Found: 14
Select item for more details and to access through your institution.
A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 5, p. 634, doi. 10.1007/s10637-017-0473-9
- By:
- Publication type:
- Article
Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 2, p. 235, doi. 10.1007/s10637-017-0439-y
- By:
- Publication type:
- Article
Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 489, doi. 10.1007/s10637-013-0050-9
- By:
- Publication type:
- Article
Microsatellite instability at tetranucleotide repeats in skin and bladder cancer.
- Published in:
- Oncogene, 2002, v. 21, n. 32, p. 4894, doi. 10.1038/sj.onc.1205619
- By:
- Publication type:
- Article
TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study.
- Published in:
- Cancer Research & Treatment, 2018, v. 50, n. 2, p. 398, doi. 10.4143/crt.2017.074
- By:
- Publication type:
- Article
A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo.
- Published in:
- PLoS ONE, 2018, v. 13, n. 1, p. 1, doi. 10.1371/journal.pone.0191046
- By:
- Publication type:
- Article
Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers.
- Published in:
- PLoS ONE, 2017, v. 12, n. 12, p. 1, doi. 10.1371/journal.pone.0189953
- By:
- Publication type:
- Article
Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility.
- Published in:
- Journal of Medical Internet Research, 2017, v. 19, n. 3, p. 1, doi. 10.2196/resprot.7289
- By:
- Publication type:
- Article
Carcinogen exposure and gene promoter hypermethylation in bladder cancer.
- Published in:
- Carcinogenesis, 2006, v. 27, n. 1, p. 112
- By:
- Publication type:
- Article
Low dose exposure to sodium arsenite synergistically interacts with UV radiation to induce mutations and alter DNA repair in human cells.
- Published in:
- Mutagenesis, 2004, v. 19, n. 2, p. 143, doi. 10.1093/mutage/geh010
- By:
- Publication type:
- Article
Development and Validation of an ERCC1 Immunohistochemistry Assay for Solid Tumors.
- Published in:
- Archives of Pathology & Laboratory Medicine, 2016, v. 140, n. 12, p. 1397, doi. 10.5858/arpa.2016-0006-OA
- By:
- Publication type:
- Article
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 93, doi. 10.1007/s00280-021-04358-3
- By:
- Publication type:
- Article
Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 4, p. 945, doi. 10.1007/s00280-010-1377-y
- By:
- Publication type:
- Article
Dose Selection for the Investigational Anticancer Agent Alisertib (MLN8237): Pharmacokinetics, Pharmacodynamics, and Exposure-Safety Relationships.
- Published in:
- Journal of Clinical Pharmacology, 2015, v. 55, n. 3, p. 336, doi. 10.1002/jcph.410
- By:
- Publication type:
- Article